AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2025
Jan 23, 2025
30751_dirs_2025-01-22_0a0b0481-2abc-48d0-8c46-95e771b7ae6b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-01-17
Reporting Person: Patil Neena M (EVP & Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-17 | Ordinary Shares | A | 5864 | $0.0 | Acquired | 39023 | Direct |
| 2025-01-17 | Ordinary Shares | F | 1905 | $122.62 | Disposed | 37118 | Direct |
Footnotes
F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.
F2: The Reporting Person acquired 111 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024.
F3: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.